The Health System in Costa Rica: Focus on the Management of Diabetes Mellitus
Abstract
Costa Rica's health system was established in 1941 by the president at the time, Rafael Angel Calderon Guardia. Since then, the public health system has expanded, and a private system was also introduced. Diabetes management differs greatly between both systems, as well as the medications available. Publicly, the system faces many challenges when treating diabetes; including a limited range and selection of medications, as well as a blatant lack of support (nutritional, physical, and psychological). Privately, the costs adjacent to a diabetes diagnosis represent an unbearable burden to some patients, with medications such as a weekly dose of 1.0 mg of semaglutide representing approximately 47.5% of Costa Rica's minimum wage. Despite its flaws, both systems provide the Costa Rican population with options for treatment. The Caja Costarricense de Seguro Social covers around 90% of the population, which puts Costa Rica on par with developed countries.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.